MODY

Please read these Terms of Use and Privacy Statement (collectively, the "Terms") carefully before using any of the box above indicates that you accept these Terms.

MODY
x

Are you interested in possibly participating in a clinical trial for Warm Autoimmune Hemolytic Anemia?

Read More

Following specialists treat  MODY. Help us improve our data based on your experience.

Based on your feedback, we will add the specialty within 1 month


Submit

100%

100%

50%

100%

50%

50%

0%20%40%60%80%

Specialty scores for MODY

Overview

Source: In partnership with Genetic and Rare Diseases Information Center, funded by the National Center for Advancing Translational Sciences, and the National Human Genome Research Institute https://rarediseases.info.nih.gov/gard.

Terms of Use

Maturity-onset diabetes of the young

overview Question

What is maturity-onset diabetes of the young (MODY)?

Maturity-onset diabetes of the young (MODY) is a form of diabetes that is characterized by an early onset diabetes.  MODY represents about 2% of all diabetes cases and is commonly misdiagnosed as type 1 or type 2 diabetes mellitus. It is due to a primary defect in pancreatic β-cell function. There are several MODY subtypes with distinct genetic causes: MODY1, caused by mutations in the HNF4A geneMODY2, caused by mutations in GCK gene; MODY3 caused by mutations in the HNFA1 (the most common type); MODY4 caused by mutations in the PDX1 gene; MODY5 caused by mutations in the HNF1B gene; MODY6 caused by mutations in the NEUROD1 gene; MODY7 caused by mutations in the KLF11 gene; MODY8 caused by mutations in the CEL gene; MODY9 caused by mutations in the PAX4 gene; MODY10 caused by mutations in the INS gene; MODY11 caused by mutations in the BLK gene; MODY12 caused by mutations in the ABCC8 gene; MODY13  caused by heterozygous mutation in the KCNJ11 gene; and MODY14 caused by mutations in the APPL1 gene. It is inherited in an autosomal dominant pattern. Treatment depends on the subtype and may include sulfonylureas, insulin or diet and exercise.

Date Modified: 2016-04-20T11:42:00

FDA Approved Medicines

  • FDA approved glipizide/metformin HCl, sold as Metaglip, manufactured by Bristol-Myers Squibb as oral tablets for the treatment of type 2 diabetes. ( MODY ) in year 2002.
  • FDA approved dulaglutide, sold as Trulicity, manufactured by Eli Lilly as to improve glycemic control in type II diabetics ( MODY ) in year 2014.
  • FDA approved insulin degludec injection, sold as Tresiba, manufactured by Novo Nordisk for glycemic control in adults with diabetes mellitus ( MODY ) in year 2015.
  • FDA approved dapagliflozin + metformin hydrochloride, sold as Xigduo XR, manufactured by AstraZeneca for glycemic control in adults with type II diabetes ( MODY ) in year 2014.
  • FDA approved rosiglitazone maleate and metformin HCl, sold as Avandamet, manufactured by GlaxoSmithKline for improvement of glycemic control in type 2 diabetes patients ( MODY ) in year 2002.
  • FDA approved exenatide, sold as Byetta, manufactured by Amylin/Eli Lilly for the adjunctive treatment of Type 2 diabetes mellitus ( MODY ) in year 2005.
  • FDA approved exenatide extended-release for injectable suspension, sold as Bydureon, manufactured by Amylin for the improvement of glycemic control in adults with type II diabetes mellitus ( MODY ) in year 2012.
  • FDA approved colesevelam hydrochloride, sold as Welchol, manufactured by Daiichi Sankyo for the improvement of glycemic control in adults with type 2 diabetes mellitus ( MODY ) in year 2008.
  • FDA approved insulin glargine [rDNA origin] injection, sold as Lantus, manufactured by Sanofi-aventis for adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia ( Hyperglycemia | Type 1 Diabetes Mellitus | MODY ) in year 2000.
  • FDA approved acarbose, sold as Precose, manufactured by Bayer for the treatment of non-insulin-dependent diabetes mellitus ( MODY ) in year 1995.
  • FDA approved pioglitazone hydrochloride and metformin hydrochloride, sold as ACTOplus met, manufactured by Takeda for the treatment of type 2 diabetes ( MODY ) in year 2005.
  • FDA approved liraglutide, sold as Victoza, manufactured by Novo Nordisk for the treatment of type 2 diabetes mellitus ( MODY ) in year 2010.
  • FDA approved saxagliptin, sold as Onglyza, manufactured by Bristol-Myers Squibb for the treatment of type 2 diabetes mellitus ( MODY ) in year 2009.
  • FDA approved pramlintide, sold as Symlin, manufactured by Amylin Pharmaceuticals for the treatment of type I and type II diabetes ( MODY ) in year 2005.
  • FDA approved insulin lispro, sold as Humalog, manufactured by Eli Lilly for the treatment of type I and type II diabetes ( MODY ) in year 1996.
  • FDA approved linagliptin, sold as Tradjenta, manufactured by Boehringer Ingelheim for the treatment of type II diabetes ( MODY ) in year 2011.
  • FDA approved empagliflozin, sold as Jardiance, manufactured by Boehringer Ingelheim for the treatment of type II diabetes ( MODY ) in year 2014.
  • FDA approved empagliflozin and metformin hydrochloride, sold as Synjardy, manufactured by Boehringer Ingelheim for the treatment of type II diabetes ( MODY ) in year 2015.
  • FDA approved linagliptin plus metformin hydrochloride, sold as Jentadueto, manufactured by Eli Lilly for the treatment of type II diabetes ( MODY ) in year 2012.
  • FDA approved sitagliptin and simvastatin, sold as Juvisync, manufactured by Merck for the treatment of type II diabetes ( MODY ) in year 2011.
  • FDA approved Glimepiride, sold as Amaryl, manufactured by Hoechst Marion Roussel for the treatment of type II diabetes ( MODY ) in year 1995.
  • FDA approved alogliptin, sold as Nesina, manufactured by Takeda for the treatment of type II diabetes mellitus ( MODY ) in year 2013.
  • FDA approved albiglutide, sold as Tanzeum, manufactured by GlaxoSmithKline for the treatment of type II diabetes mellitus ( MODY ) in year 2014.
  • FDA approved canagliflozin, sold as Invokana, manufactured by Janssen Pharmaceuticals for the treatment of type II diabetes mellitus ( MODY ) in year 2013.
  • FDA approved rosiglitazone maleate, sold as Avandia, manufactured by SmithKline Beecham for the treatment of type II diabetes mellitus ( MODY ) in year 1999.
  • FDA approved miglitol, sold as Glyset, manufactured by Bayer for the treatment of Type II (non-insulin-dependent) diabetes mellitus ( MODY ) in year 1996.
  • FDA approved sitagliptin phosphate, sold as Januvia, manufactured by Merck for the treatment of type II diabetes ( MODY ) in year 2006.
  • FDA approved dapagliflozin, sold as Farxiga, manufactured by Bristol-Myers Squibb for the treatment of type II diabetes ( MODY ) in year 2014.